Bayer Buying VC-backed Direvo Biotech
Bayer HealthCare has agreed to acquire Direvo Biotech AG, a Germany-based developer of a protein engineering platform that uses high-throughput technologies for the discovery and optimization of biopharmaceuticals. The deal is valued at approximately €210 million in cash. Direvo has raised around $42 million in VC funding since 2000, from firms like TVM Capital, Signet Healthcare Partners, Danisco Ventures, Mulligan BioCapital and NRW Bank.
16 September 2008•4 mins read
